Rouven Müller
Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study.
Tamò R, Turk T, Böni J, Kouyos R, Schmutz S, Huber M, Shah C, Bischoff-Ferrari H, Distler O, Battegay E, Giovanoli P, Guckenberger M, Kohler M, Müller R, Petry H, Ruschitzka F, McGeer A, Sax H, Weber R, Trkola A, Kuster S. Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infect Control Hosp Epidemiol 2021; 43:312-318.
May 6, 2021Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study.
May 6, 2021Infect Control Hosp Epidemiol 2021; 43:312-318
Tamò Raphaël, Turk Teja, Böni Jürg, Kouyos Roger D, Schmutz Stefan, Huber Michael, Shah Cyril, Bischoff-Ferrari Heike A, Distler Oliver, Battegay Edouard, Giovanoli Pietro, Guckenberger Matthias, Kohler Malcolm, Müller Rouven, Petry Heidi, Ruschitzka Frank, McGeer Allison, Sax Hugo, Weber Rainer, Trkola Alexandra, Kuster Stefan
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2018
Nov 2, 2018Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Nov 2, 2018Bone Marrow Transplant 2018
Ghilardi Guido, Ghielmini Michele, Wannesson Luciano, Lerch Erika, Samaras Panagiotis, Schanz Urs, Passweg Jakob R, Stussi Georg, Kleber Martina, Gerber Bernhard, Rossi Davide, Schmidt Adrian, Pabst Thomas, Jeker Barbara, Müller Rouven, Cairoli Anne, Müller Antonia M S, Bargetzi Mario, Hitz Felicitas, Baldomero Helen, Heim Dominik, Swiss Blood Stem Cell Transplantation Registry
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo